Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kazia Therapeutics (KZIA) Current Deferred Revenue (2016 - 2018)

Kazia Therapeutics (KZIA) posted Current Deferred Revenue of $104471.1 for Q2 2018, up 239.2% on a QoQ basis from $30799.6 in Q2 2017, and up 239.2% year-over-year from $30799.6 in Q2 2017.

Kazia Therapeutics (KZIA) has 3 years of Current Deferred Revenue data on file, last reported at $104471.1 in Q2 2018.

  • In Q2 2018, Current Deferred Revenue rose 239.2% year-over-year to $104471.1; the TTM figure through Jun 2018 stood at $104471.1 (up 239.2% YoY), while the FY2018 annual figure was $104471.1, up 239.2% from the prior year.
  • Current Deferred Revenue grew to $104471.1 in Q2 2018, from $30799.6 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $137892.6 in Q4 2016 and bottomed at $30617.0 in Q2 2016.
  • A 3-year average of $75945.1 and a median of $67635.4 in 2017 frame the typical range for Current Deferred Revenue.
  • Annual changes were most pronounced in 2017 — Current Deferred Revenue advanced 0.6% — and 2018, when it jumped 239.2%.
  • Year by year, Current Deferred Revenue stood at $137892.6 in 2016, then tumbled by 77.66% to $30799.6 in 2017, then jumped by 239.2% to $104471.1 in 2018.
  • The last three Current Deferred Revenue figures came in at $104471.1 (Q2 2018), $30799.6 (Q2 2017), and $137892.6 (Q4 2016), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Kazia Therapeutics 1.55 Bn 1.55 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2018 104,471.09
Jun 30, 2017 30,799.62
Dec 31, 2016 137,892.62
Jun 30, 2016 30,617.04